Jiangsu Enhua Pharmaceutical Co., Ltd. (002262)

Jiangsu Enhua Pharmaceutical Co., Ltd. (002262)

Founded in 1978, Jiangsu Enhua Pharmaceutical Co., Ltd. was listed on Shenzhen Stock Exchange in 2008 with the stock code of 002262. It is a pharmaceutical enterprise integrating science, industry and trade, a national designated production unit of psychotropic drugs, a national high-tech enterprise, a national top 100 pharmaceutical enterprise, a national technological innovation demonstration enterprise and a national intellectual property demonstration unit, National "20 years and 20 stars" pharmaceutical quality management enterprise star unit, international environmental certification (ISO14000) enterprises, the first batch of innovative enterprises in Jiangsu Province, vice president unit of China narcotic drugs Association, vice president unit of Jiangsu Pharmaceutical Industry Association.

The company is mainly engaged in the production and operation of central nervous system drugs. Its strategic positioning is in the market of central nervous system drugs. It is mainly engaged in the development, production and sales of central nervous system drugs. It is an enterprise focusing on the market segmentation of central nervous system drugs, mainly including anesthesia, psychiatric and neurology. Through years of unremitting efforts in product development, production and service, The company has established a complete product series and marketing network of central nervous system drugs, striving to build an important manufacturer and distributor of central nervous system drugs in China. In addition, the company has a series of cardiovascular and cerebrovascular products in different research and development stages, with new chemical structure and mechanism of action, and gradually involved in the market of cardiovascular and cerebrovascular drugs with broad prospects.

It has three large-scale GMP production bases for raw materials and pharmaceutical preparations, covering a total area of more than 900 mu. The enterprise has national certified workshops for raw materials, solid preparations, water injections, freeze-dried powder injections, and more than 10 automatic production lines for tablets, capsules, water injections, and powder injections. At present, there are 33 kinds of API, 300 tons / year; There are more than 100 kinds of Western medicine preparations, with a production scale of 3 billion tablets / year of solid preparations and 100 million injections / year.

According to the development strategy of the enterprise, we have made great efforts to save energy, reduce consumption and protect the environment, passed the international environmental certification (ISO14000), vigorously developed the export business of API, and carried out the EU edmf and FDA certification, striving to gain a place in the international market.

The company attaches great importance to technological innovation and new product development, and strengthens the combination of industry, University and research. The technology center of the group is the national recognized enterprise technology center and provincial engineering technology research center, with enterprise academician workstation, National Postdoctoral research workstation and National Postdoctoral innovation center, undertaking a number of national key scientific research projects.

>>server parts deals for server parts picker Tungsten Rings for Men and Women boxing equipment for sale